For some time now solid tumours has been seen as the next big battleground for CAR-T therapy, but based on the underwhelming early data released yesterday at the AACR meeting the best that can be said is that the jury is still out. A very early trial of Novartis and the University of Pennsylvania’s CART -meso failed to generate any responses and, more worryingly, reported poor persistence of the CAR-T cells.
